Conference Reports for NATAP

Back

17th European AIDS Conference November 6-9 2019, Basel     Aging with HIV (01/22/20)   High HCV re infection rate in MSM living with HIV in Barcelona: The need to focus on high risk population to achieve HCV elimination (01/17/20)   Global prevalence of liver impairment in HIV population in direct antiviral agents (DAA) era: the role of fatty liver disease (01/13/20)   Hepatic steatosis in HIV+ individuals: which impact has baseline BMI and treatment with integrase inhibitors? (01/13/20)   Evolutive NAFLD predicts frailty in people living with HIV - Mark Mascolini (01/13/20)   Integrase inhibitors dolutegravir and raltegravir exert proadipogenic and profibrotic effects and induce insulin resistance in adipose tissue and adipocytes (12/12/19)   Comparable effectiveness of Raltegravir-based dual therapy versus other regimes in patients switched for maintenance (12/09/19)   Real World Utilisation of Raltegravir 1200mg Once Daily (The RETRO Study) (12/09/19)   Depression and kynurenine/tryptophan ratio in people living with HIV (12/03/19)   Restless legs syndrome and health-related quality of life in HIV: results from the POPPY sleep substudy (12/03/19)   AIDS DEFINING AND NON-DEFINING CANCERS IN PERSONS LIVING WITH HIV IN A SINGLE CENTER COHORT FOLLOWED SINCE 1986 (12/03/19)   Non-Alcoholic Fatty Liver Disease is a significant predictor of cardiovascular risk in HIV-mono-infected patients (12/03/19)   Long-acting antiretroviral drugs / Marta Boffito MD (12/03/19)   Pharmacokinetics of Cabotegravir and Rilpivirine Long-Acting Injectables in HIV-Infected Individuals Through 48 Weeks in the FLAIR and ATLAS Phase 3 Studies (12/02/19)   Prevalence of InSTI resistance and effectiveness of InSTI-based regimens in HIV-infected patients: results from a European cohort study (12/02/19)   HIV infection in individuals seeking post-exposure prophylaxis (PEP): a retrospective data linkage study (12/02/19)   Injectable Long Acting Antiretroviral for HIV Treatment or Prevention: The ANRS CLAPT Study (12/02/19)   Will HIV-infected patients Taking Oral ARV Switch to Long-Acting Injectable ART when It Becomes Available? (12/02/19)   POPULATION PHARMACOKINETIC ANALYSIS OF DOLUTEGRAVIR IN HIV/TB COINFECTED PEOPLE WITH AND WITHOUT RIFAMPICIN (11/26/19)   Dolutegravir-based regimens are associated with weight gain over two years following ART-initiation in ART-naïve people living with HIV (PLWH) (11/26/19)   POPULATION PHARMACOKINETIC ANALYSIS OF DOLUTEGRAVIR IN HIV/TB COINFECTED PEOPLE WITH AND WITHOUT RIFAMPICIN (11/26/19)   Characterizations of weight gain following antiretroviral regimen initiation in treatment-naïve individuals living with HIV (11/26/19)   Comparison of a Two-Drug Regimen (Dolutegravir/Rilpivirine) to Standard Three-Drug Regimens in Virologically Suppressed, Treatment Experienced Individuals in the Real World (11/26/19)   COPEDOL: a two-year French multicentric, observational, longitudinal retro-prospective study in pretreated HIV-1-infected patients starting dolutegravir based regimen due to treatment failure (11/26/19)   Baseline characteristics in JUNGLE, a German observational cohort study of Juluca as 2-Drug Regimen in virologically suppressed patients, compared to the phase-3 SWORD 1 & 2 study populations (11/26/19)   SWORD-1&-2: MAINTENANCE OR IMPROVEMENT IN RENAL FUNCTION IN PLWH THROUGH 148 WEEKS AFTER SWITCH TO THE DOLUTEGRAVIR + RILPIVIRINE 2-DRUG REGIMEN (11/26/19)   A Phase 3b Open-Label Pilot Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/TenofovirAlafenamide(E/C/F/TAF) in Virologically-Suppressed HIV-1 Infected Adults Harboring the NRTI Resistance Mutation M184V/I (GS-US-292-1824): Week 24 Results (11/25/19)   Changes in LDL After Switch from TDF to TAF in the U.S. (11/25/19)   Biologic Sex Is Not the Only Difference Between Men and Women: Data From the Doravirine Phase 2/3 Clinical Trials (11/25/19)   Islatravir Efficacy and Safety for Selected Demographic and Baseline Subgroups From a Phase 2 Trial In Treatment-naïve Adults With HIV-1 Infection (11/25/19)   Subclinical atherosclerosis burden by ultrasound in carotid and femoral territories in HIV subjects: relationships with HIV and non-HIV related factors (11/22/19)   Retrospective analysis of co-medication patterns among patients treated for HIV, and potential interactions with antiviral treatment, in Norway during 2012-2018 using the Norwegian population-based prescription database (11/22/19)   Untreated HCV in HIV/HCV-Coinfected US Population Despite an Abundance of Curative Therapies (11/22/19)   Unsupressed HIV in USA: 40% >55 Years Old Unsuppressed - CDC Reports (11/22/19)   Comparison of changes in bone microarchitecture with abacavir-lamivudine versus tenofovir disoproxil fumarate-emtricitabine in adults living with HIV Greater BMD Decline With TDF Than ABC, But Similar Drop in Trabecular Bone Score - Mark Mascolini (11/21/19)   The ADVANCE trial: the impact of DXA-assessed bone mineral density of TDF/FTC/EFV and TDF/FTC+DTG versus TAF/FTC+DTG South Africa - Mark Mascolini (11/21/19)   More Antimicrobial Prescriptions May Be Clue to Undiagnosed HIV - Mark Mascolini- (11/21/19)   Only 1% HIV Diagnosis Rate More Than 6 Months After PEP in 975 People - Mark Mascolini (11/21/19)   Incidence of CKD With TDF and Non-TDF Containing Antiretroviral Regimens by Baseline D:A:D CKD Risk In People Living With HIV - (11/20/19)   Outcomes of antiretrovirals used as the third drug in subgroups of treatment naïve individuals living with HIV - (11/18/19)   Baseline and Emergent Genotypic and Phenotypic Results in HIV-1-Infected, Heavily Treatment-Experienced (HTE) Participants Meeting Protocol-Defined Virologic Failure (PDVF) Criteria Through Week 96 in the Fostemsavir (FTR) Phase 3 BRIGHTE Study - (11/18/19)   Impact of Susceptibility Scoring on Virologic Response in Heavily Treatment-Experienced Participants with HIV-1 Receiving a Fostemsavir-Based Antiretroviral Regimen: Week 96 Results from the Randomized Cohort of the Phase 3 BRIGHTE Study - (11/18/19)   Absence of Naturally Existing Resistance Against The HIV-1 Capsid Inhibitor GS-6207 in HIV-1 Primary Isolates - (11/18/19)   Impact of Susceptibility Scoring on Virologic Response in Heavily Treatment-Experienced Participants with HIV-1 Receiving a Fostemsavir-Based Antiretroviral Regimen: Week 96 Results from the Randomized Cohort of the Phase 3 BRIGHTE Study - (11/18/19)   Absence of Naturally Existing Resistance Against The HIV-1 Capsid Inhibitor GS-6207 in HIV-1 Primary Isolates - (11/18/19)   HIV-1 from antiretroviral-naïve and experienced patients lack capsid substitutions associated with GS-6207 in vitro resistance - (11/18/19)   Phase 3 Randomized, Controlled DISCOVER Study of Daily F/TAF or F/TDF for HIV Pre-exposure Prophylaxis: Week 96 Results - (11/14/19)   Longer ART Linked to Clearance of High-Risk HPV in MSM With HIV - Mark Mascolini - (11/14/19)   Rapid Initiation of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Patients With Human Immunodeficiency Virus (HIV)-1 Infection: Age, Race/Ethnicity, and Gender Subgroup Analyses From the DIAMOND Study - (11/14/19)   Prevalence of Archived HIV-1 DNA Resistance-associated Mutations and their Lack of Effect on Virologic Outcome at Week 96 in Antiretroviral Treatment-experienced, Virologically Suppressed Patients Receiving the Once-daily, Single-tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in the EMERALD Phase III Trial - (11/14/19)   Short-term Neuropsychiatric Tolerability of Bictegravir Combined with FTC/TAF in Clinical Practice - (11/14/19)   EACS New Aging/Screening Guidelines / HIV+ Case 69 Year Old Aging in Spain - Brighton UK Geriatric HV Clinic - (11/14/19)   Maintenance DTG/3TC Controls HIV in People With Historical 3TC Resistance "Dolutegravir and lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a pilot clinical trial (ART-PRO)" - Mark Mascolini - (11/14/19)   More Than Half of Adult Group With Perinatal HIV Have Neurocognitive Impairment - Mark Mascolini - (11/13/19)   Fibrosis, Steatosis, and NAFLD Boost Odds of Frailty in HIV Group - Mark Mascolini (11/13/19)   Short-term Neuropsychiatric Tolerability of Bictegravir Combined with FTC/TAF in Clinical Practice - (11/13/19)   Real world data of using Triumeq (dolutegravir/abacavir/lamivudine; DTG/ABC/3TC): final outcomes of the 3-year German TRIUMPH cohort show good virologic effectiveness and safety in routine clinical practice - (11/13/19)   Dolutegravir (DTG) Use During Pregnancy and Birth Outcomes: Data from the Antiretroviral Pregnancy Registry (APR) - (11/13/19)   SWITCHING TO DTG/3TC FIXED-DOSE COMBINATION (FDC) IS NON-INFERIOR TO CONTINUING A TAF-BASED REGIMEN THROUGH 48 WEEKS: SUBGROUP ANALYSES FROM THE TANGO STUDY - (11/13/19)   Precancer Anal Lesion Arises in 10% of Australian MSM--But Clearance Common - Mark Mascolini - (11/13/19)   Phase 3 Randomized, Controlled DISCOVER Study of Daily F/TAF or F/TDF for HIV Pre-exposure Prophylaxis: Week 96 Results - (11/13/19)   Safety and Efficacy of Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People With HIV Aged 50 Years and Older - (11/12/19)   DISCOVER in Europe: a Subanalysis of the Phase 3, Randomized, Controlled Trial of Daily Emtricitabine/Tenofovir Alafenamide or Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Pre-exposure Prophylaxis - (11/12/19)   Long-term Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in ART-Naïve Adults - (11/12/19)   Switching to Bictegravir/Emtricitabine/TenofovirAlafenamide(B/F/TAF) in Adults Aged ≥ 65 Years: Week 48 Results from a Phase 3b, Open-Label Trial (GS-US-380-4449) - (11/12/19)   Sustained Viral Suppression among Participants with Pre-existing M184V/I Who Switched to Bictegravir/Emtricitabine/TenofovirAlafenamide - (11/12/19)   Risk Score Predicts Diabetes Better Than HOMA-IR and Other Equations "Comparing a risk score against physiological markers for predicting diabetes incidence in HIV+ individuals" - (11/12/19)   New HIV Comorbidity Index Linked to Mortality, Can Outperform Other Tools - (11/12/19)   One Third of MSM PrEP Users in French Analysis Quit in 30 Months - Mark Mascolini - (11/12/19)   Switch From TDF to TAF in HIV/HBV+ Maintains Viral Control, Helps Kidneys - Mark Mascolini (11/12/19)   INI Resistance Remains Rare in INI-Naive--Initial CD4, Viral Load Predict Failure - Mark Mascolini - (11/12/19)   Integrase Inhibitors Tied to Weight Gain, Hepatic Steatosis in Longitudinal Cohort - Mark Mascolini - (11/12/19)   Is modern antiretroviral therapy causing weight gain? - (11/12/19)   Prevalence of and risk factors for low Bone Mineral Density assessed by Quantitative Computed Tomography in people living with HIV and uninfected controls Very Low BMD More Frequent With HIV--But Not After Statistical Adjustment - Mark Mascolini - (11/12/19)   Single Doses of Long-Acting Capsid Inhibitor GS-6207 Administered by Subcutaneous Injection Are Safe and Efficacious in People Living With HIV - (11/12/19)   GS-6207 Long Acting Capsid Inhibitor Safety & PK Subcutaneous - (11/12/19)   Safety and Efficacy of Triple Therapy with Dolutegravir plus 2 NRTIs, in Treatment-Naïve HIV-2 Infected Patients - 48 weeks results from a Phase II Study in Portugal - (11/12/19)   Non inferiority of dolutegravir+emtricitabine dual therapy to standard combination antiretroviral therapy in maintaining HIV suppression throughout 48 weeks: The SIMPL'HIV study - (11/12/19)   The ADVANCE clinical trial: changes from baseline to week 96 in DXA-assessed body composition in TAF/FTC+DTG compared to TDF/FTC+DTG, and TDF/FTC/EFV Weight Keeps Rising Through 96 Weeks With TAF/FTC+DTG in Black Africans - (11/12/19)   ASSESSMENTS OF VERY-LOW-LEVEL HIV REPLICATION FOR DOLUTEGRAVIR + LAMIVUDINE (DTG + 3TC) VS DOLUTEGRAVIR + TENOFOVIR DISOPROXIL/EMTRICITABINE (DTG + TDF/FTC) IN THE GEMINI-1&-2 STUDIES THROUGH WEEK 96 - (11/08/19)   Uptake and discontinuation of Integrase Inhibitors (INSTIs) in a large cohort setting (DTG, EVG, RAL) DTG Easily Most Popular INI Across Europe, With Lowest Quitting Rate - Mark Mascolini (11/08/19)   Changes in bone mineral density in men who have sex with men on tenofovir disoproxil fumarate-based HIV pre-exposure prophylaxis: longitudinal cohort data - (11/08/19)   BMD Drops More Than 3% in up to One Third of MSM Using TDF PrEP for 2 Years - Mark Mascolini - (11/08/19)   Maintenance DTG/3TC Controls HIV in People With Historical 3TC Resistance "Dolutegravir and lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a pilot clinical trial (ART-PRO)" - Mark Mascolini - (11/08/19)   Changes in weight after switching to dolutegravir containing antiretroviral therapy in the Swiss HIV Cohort Study - (11/08/19)   Shorter time to treatment failure in PLHIV switched to dolutegravir plus either rilpivirine or lamivudine compared to integrase inhibitor-based triple therapy in a large Spanish cohort - VACH Doubled Failure Risk After Switch to DTG/RPV or DTG/3TC Versus Triple-INI Regimen - Mark Mascolini - (11/08/19)   Menopause Does Not Affect HIV or CD4 Response in Multicenter Spanish Group - Mark Mascolini - (11/08/19)   Pregnancies and Live Births Stable/Rising Since 2002 in European Women With HIV - Mark Mascolini - (11/08/19)   Outcomes for Women in Phase 3 Trials of Long-Acting Cabotegravir + Rilpivirine: Pooled ATLAS and FLAIR Week 48 Results - (11/08/19)   Are new antiretroviral treatments increasing the risks of obesity? - (11/08/19)   Long-term Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in ART-Naïve Adults - (11/08/19)   Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide vs comparators in cis-women and girls (living with HIV): an analysis of 5 clinical trials - Mark Mascolini - (11/07/19)   Switching to DTG/3TC Fixed-Dose Combination (FDC) Is Non-inferior to Continuing a TAF-Based Regimen Through 48 Weeks: Subgroup Analyses From the TANGO Study - (11/07/19)   Once-a-Month CAB/RPV Effective in Women--Fewer Adverse Events Than Men - Mark Mascolini - (11/07/19)   Incidence of CKD with TDF and non-TDF containing antiretroviral regimens by baseline D:A:D CKD risk in people living with HIV (PLWH) - Mark Mascolini - (11/07/19)   Modest 96-Week Weight Gain in Trials of Doravirine, Darunavir, Efavirenz "EFFECT OF DORAVIRINE ON BODY WEIGHT AND BODY MASS INDEX IN TREATMENT NAïVE ADULTS WITH HIV-1" - Mark Mascolini - (11/07/19)   Weight Keeps Rising Through 96 Weeks With TAF/FTC+DTG in Black Africans - ADVANCE Study - Mark Mascolini - (11/07/19)   Delayed Weight Gain in Immediate Versus Deferred ART Arm in START - "Antiretroviral therapy and body weight in the START (Strategic Timing of Antiretroviral Treatment) trial" - Mark Mascolini - (11/07/19)   Switch to INI Does Not Affect Average Weight Gain in Middle-Aged/Older Group - Mark Mascolini - (11/07/19)   Will HIV-infected patients Taking Oral ARV Switch to Long-Acting Injectable ART when It Becomes Available? - (11/06/19)   Outcomes of antiretrovirals used as the third drug in subgroups of treatment naïve individuals living with HIV - (11/06/19)   Gilead's Biktarvy Maintained High Efficacy With No Cases of Treatment-Emergent Resistance Through Three Years in Phase 3 HIV Clinical Trials - (11/06/19)   Gilead Presents 96-week Discover Trial Data Supporting Non-inferior Efficacy and Key Safety Differences of Descovy For PrEP™ Compared With Truvada For PrEP® - (11/06/19)   EACS 2019: ViiV Healthcare to present 17 abstracts from its portfolio addressing the diverse needs of people living with HIV - PRESS RELEASE - (11/06/19)   Screening Program Cuts Anal Cancer Precursor Rate in 405 MSM With HIV - Mark Mascolini (11/06/19)   Long-term Antilipid Therapy Tied to 70% Lower Death Risk in VA Cohort - Mark Mascolini (11/06/19)   French Studies Find Eagerness for Long-Term Injectables--With Key Cautions - Mark Mascolini (11/06/19)   No Change in Kidney Function, Cholesterol Ratio, or Weight When 60+ Group Switches to TAF - Mark Mascolini (11/06/19)   Response Differences Between First-Line Regimens in Large European Group - Mark Mascolini (11/06/19)